Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Sarcoma 2Rhabdomyosarcoma 2Neoplasm Metastasis 2Medulloblastoma 2Uveal Melanoma 1Small Cell Lung Carcinoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Mesothelioma 1Melanoma 1Laryngeal Diseases 1Glioma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × LY2940680 × Clear all
NCT01226485 2019-09-13

A Study in Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
84 enrolled 22 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡